thiazolidines has been researched along with Bone Loss, Osteoclastic in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boonen, S; Deacon, S; Eastell, R; Kuwayama, T; Nagase, S; Ohyama, M; Small, M; Spector, T | 1 |
| Deacon, S; Hashimoto, Y; Kuwayama, T; Manako, J; Nagase, S; Ohyama, M; Sharpe, J; Small, M | 1 |
| Gamsjäger, M; Resch, H | 1 |
| Deacon, S; Dijk, DJ; Eastell, R; Greenwood, A; Sharpe, J; Small, M; Tanimoto, M; Yamada, H; Yuba, M | 1 |
| Hashimoto, Y; Kawabata, K; Kawada, N; Kayasuga, R; Kunishige, A; Mori, H; Nakanishi, Y; Nishikawa, S; Ochi, Y; Sugitani, M; Tanaka, M; Yamada, H | 1 |
| Boonen, S; Claessens, F; Papapoulos, S; Rosenberg, E; Vanderschueren, D | 1 |
| Deacon, S; Hashimoto, Y; Kuwayama, T; Nagase, S; Ohyama, M; Small, M | 1 |
2 review(s) available for thiazolidines and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
[Cathepsin K antagonists: preclinical and clinical data].
Topics: Biphenyl Compounds; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cathepsin K; Clinical Trials as Topic; Drug Evaluation, Preclinical; Female; Humans; Osteoclasts; Osteoporosis, Postmenopausal; Thiazolidines | 2015 |
Inhibition of cathepsin K for treatment of osteoporosis.
Topics: Alkaline Phosphatase; Animals; Biphenyl Compounds; Bone Density; Bone Remodeling; Bone Resorption; Cathepsin K; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Thiazolidines | 2012 |
4 trial(s) available for thiazolidines and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cathepsin K; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteogenesis; Osteoporosis, Postmenopausal; Thiazolidines; Time Factors | 2014 |
Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women.
Topics: Aged; Alendronate; Area Under Curve; Bone and Bones; Bone Density; Bone Resorption; Cathepsin K; Collagen Type I; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Single-Blind Method; Thiazolidines | 2015 |
Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Cathepsin K; Circadian Clocks; Collagen Type I; Cross-Over Studies; Drug Administration Schedule; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Single-Blind Method; Thiazolidines | 2016 |
Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.
Topics: Administration, Oral; Aged; Area Under Curve; Biomarkers; Bone Resorption; Cathepsin K; Collagen Type I; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Thiazolidines | 2012 |
1 other study(ies) available for thiazolidines and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism.
Topics: Actins; Administration, Oral; Animals; Biomarkers; Bone and Bones; Bone Remodeling; Bone Resorption; Calcium; Cathepsin K; Collagen Type I; Female; Haplorhini; Humans; Male; Osteogenesis; Parathyroidectomy; Peptides; Protease Inhibitors; Rats; Thiazolidines | 2011 |